From: Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations
GENE
Antibody
Result
MLH1
G168-15
Normal expression
PMS2
A16-4
Normal expression.
MSH6
BC/44
Loss of expression.
MSH2
FE11